B. Metzler seel. Sohn & Co. AG Buys New Stake in Denali Therapeutics Inc. $DNLI

Key Points

• Institutional buying increased: B. Metzler seel. Sohn & Co. acquired 112,300 Denali Therapeutics shares valued at approximately $2.9 million. Institutional investors and hedge funds collectively own 92.92% of DNLI.
• Analysts remain broadly optimistic: Thirteen analysts rate DNLI a Buy, with an average “Moderate Buy” rating and a consensus price target of $35.92, above the reported share price of $24.92.
• Quarterly results were mixed: Denali reported a loss of $0.68 per share, missing estimates of a $0.51 loss, while revenue of $3.6 million exceeded expectations of $2.15 million. The clinical-stage biotech develops treatments for neurodegenerative diseases, including Parkinson’s and Alzheimer’s.

B. Metzler seel. Sohn & Co. AG bought a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 112,300 shares of the company's stock, valued at approximately $2,888,000. B. Metzler seel. Sohn & Co. AG owned 0.07% of Denali Therapeutics as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in DNLI. BlackRock Inc. purchased a new position in Denali Therapeutics during the 2nd quarter valued at about $360,759,000. Vanguard Group Inc. grew its position in Denali Therapeutics by 8.9% in the 4th quarter. Vanguard Group Inc. now owns 13,057,890 shares of the company's stock valued at $215,586,000 after acquiring an additional 1,064,972 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its stake in Denali Therapeutics by 28.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company's stock worth $119,766,000 after purchasing an additional 1,615,565 shares during the period. Temasek Holdings Private Ltd increased its stake in Denali Therapeutics by 30.9% during the fourth quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company's stock worth $115,784,000 after purchasing an additional 1,657,142 shares during the period. Finally, State Street Corp increased its stake in Denali Therapeutics by 14.6% during the fourth quarter. State Street Corp now owns 6,263,371 shares of the company's stock worth $103,408,000 after purchasing an additional 799,110 shares during the period. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Wedbush reissued an "outperform" rating and issued a $26.00 price objective on shares of Denali Therapeutics in a research note on Monday, July 13th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Denali Therapeutics from $31.00 to $35.00 and gave the stock a "buy" rating in a research note on Thursday, July 16th. JPMorgan Chase & Co. began coverage on shares of Denali Therapeutics in a report on Monday, July 13th. They set an "overweight" rating and a $29.00 target price on the stock. Stifel Nicolaus set a $41.00 price target on shares of Denali Therapeutics in a research report on Monday, June 22nd. Finally, UBS Group raised their price target on shares of Denali Therapeutics from $25.00 to $34.00 and gave the company a "buy" rating in a research report on Friday, August 7th. Thirteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Denali Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $35.92.

Insider Buying and Selling

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,857 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total value of $71,624.99. Following the sale, the insider directly owned 281,763 shares of the company's stock, valued at approximately $7,063,798.41. This represents a 1.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 9.70% of the stock is owned by company insiders.

Denali Therapeutics Stock Performance

Shares of DNLI opened at $24.92 on Friday. Denali Therapeutics Inc. has a 1 year low of $12.58 and a 1 year high of $27.30. The stock has a market capitalization of $3.98 billion, a PE ratio of -8.77 and a beta of 1.01. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.32 and a current ratio of 8.37. The stock has a 50-day simple moving average of $24.45 and a 200-day simple moving average of $21.61.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.17). The company had revenue of $3.60 million for the quarter, compared to analysts' expectations of $2.15 million. During the same quarter last year, the firm earned ($0.72) EPS. On average, analysts predict that Denali Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source